Clinical management of cannabis withdrawal.
Connor JP, Stjepanović D, Budney AJ, Le Foll B, Hall WD.
Addiction. 2022 Jul;117(7):2075-2095. doi: 10.1111/add.15743. Epub 2022 Jan 10.
Pharmacokinetics and pharmacodynamics of cannabinoids.
Grotenhermen F.
Clin Pharmacokinet. 2003;42(4):327-60. doi: 10.2165/00003088-200342040-00003.
New psychoactive substances: a review and updates.
Shafi A, Berry AJ, Sumnall H, Wood DM, Tracy DK.
Ther Adv Psychopharmacol. 2020 Dec 17;10:2045125320967197. doi: 10.1177/2045125320967197. eCollection 2020.
E-cigarette vaping associated acute lung injury (EVALI): state of science and future research needs.
Marrocco A, Singh D, Christiani DC, Demokritou P.
Crit Rev Toxicol. 2022 Mar;52(3):188-220. doi: 10.1080/10408444.2022.2082918. Epub 2022 Jul 13.
Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications.
Bilbao A, Spanagel R.
BMC Med. 2022 Aug 19;20(1):259. doi: 10.1186/s12916-022-02459-1.
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action.
Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A, Vogel H, Hell D.
Neuroreport. 1998 Dec 1;9(17):3897-902. doi: 10.1097/00001756-199812010-00024.
Evidence for a hallucinogen dependence syndrome developing soon after onset of hallucinogen use during adolescence.
Stone AL, Storr CL, Anthony JC.
Int J Methods Psychiatr Res. 2006;15(3):116-30. doi: 10.1002/mpr.188.
Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study.
Noller GE, Frampton CM, Yazar-Klosinski B.
Am J Drug Alcohol Abuse. 2018;44(1):37-46. doi: 10.1080/00952990.2017.1310218. Epub 2017 Apr 12.
Pharmacotherapies for cannabis use disorder.
Spiga F, Parkhouse T, Tang VM, Savović J, Le Foll B, Nielsen S.
Cochrane Database Syst Rev. 2025 Sep 30;9(9):CD008940. doi: 10.1002/14651858.CD008940.pub4.
Neurobiology of addiction and implications for treatment.
Lingford-Hughes A, Nutt D.
Br J Psychiatry. 2003 Feb;182:97-100. doi: 10.1192/bjp.182.2.97.
